Intervention not reported
Cramp frequency (mean number of cramps per week on treatment at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in cramp frequency (mean number of cramps per week on treatment at 4… (moderate certainty).
1 finding from 1 review
Intervention not reported
Cramp intensity (moderate or worse at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in cramp intensity (moderate or worse at 4 weeks) (moderate certainty).
1 finding from 1 review
Intervention not reported
Cramp duration (≥ 1 minute at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in cramp duration (≥ 1 minute at 4 weeks) (low certainty).
1 finding from 1 review
Intervention not reported
Major adverse events · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
It is very uncertain whether the intervention changes major adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Minor adverse events · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in minor adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Cramp frequency (percentage change from baseline at 4 weeks) · pregnant women with leg cramps
1 finding from 1 review
Intervention not reported
Cramp frequency (responder analysis: 25% or better reduction at 4 weeks) · pregnant women with leg cramps
1 finding from 1 review
Disability due to FAP progression Not measured · people with early‐stage TTR‐FAP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (mental) · people with TTR‐FAP
1 finding from 1 review
Has died · people with TTR‐FAP
It is very uncertain whether diflunisal changes number of participants who died during the trial compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
It is very uncertain whether diflunisal changes number of dropouts due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of participants experiencing at least one severe adverse event · people with TTR‐FAP
It is very uncertain whether diflunisal changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).
1 finding from 1 review
Disability due to FAP progression (expressed as the change in R‐ODS) Scale from: 0 (worst disability) to 48 (normal) · people with TTR‐FAP
1 finding from 1 review
Severity of peripheral neuropathy (expressed as the change in mNIS+7ALN) Scale from: 0 (normal) to 304 (total impairment) · people with TTR‐FAP
1 finding from 1 review
QoL · people with TTR‐FAP
1 finding from 1 review
Has died · people with TTR‐FAP
Patisiran showed no clear difference in number of participants who died during the trial compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
Patisiran may leads to lower number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing at least one severe adverse event · people with TTR‐FAP
Patisiran showed no clear difference in number of participants experiencing at least one severe adverse event compared with placebo (low certainty).
1 finding from 1 review
Severity of peripheral neuropathy (expressed as the change in NIS‐LL) Scale from: 0 (normal) to 88 (total impairment) · people with early‐stage TTR‐FAP
1 finding from 1 review
Disability due to FAP progression Not measured · people with TTR‐FAP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found